MedTrace Logo

Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

NCT05036824 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-09-08

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the current management approach with "intermediate" or "therapeutic" doses of tinzaparin for thromboprophylaxis in hospitalized patients, non on ICU organ support, with confirmed COVID-19.

Conditions

  • Covid19
  • Hospitalization

Interventions

DRUG

tinzaparin

Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU

Sponsors & Collaborators

  • University Hospital of Patras

    lead OTHER

Principal Investigators

  • Karolina Akinosoglou, MD,PhD · University Hospital of Patras

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-03-31
Completion
2022-04-30
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05036824 on ClinicalTrials.gov